New PARP inhibitor AZD5305 enters human trials for multiple advanced cancers
NCT ID NCT04644068
First seen Feb 21, 2026 · Last updated Jun 21, 2026 · Updated 20 times
Summary
This study tests an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors like ovarian, breast, pancreatic, and prostate cancer. The drug is given alone or combined with other anti-cancer agents. The main goals are to check safety, tolerability, and early signs of tumor shrinkage. About 702 participants will take part across multiple sites.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Oklahoma City, Oklahoma, 73104, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Heidelberg, 3084, Australia
-
Research Site
Melbourne, 3000, Australia
-
Research Site
Vancouver, British Columbia, V5Z 1K1, Canada
-
Research Site
Toronto, Ontario, M5G 2M9, Canada
-
Research Site
Montreal, Quebec, H2X 0A9, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
Beijing, 100142, China
-
Research Site
Changchun, 130021, China
-
Research Site
Changsha, 410013, China
-
Research Site
Chengdu, 610041, China
-
Research Site
Chongqing, 400030, China
-
Research Site
Guangzhou, 510060, China
-
Research Site
Harbin, 150081, China
-
Research Site
Jining, 272029, China
-
Research Site
Shandong, China
-
Research Site
Shanghai, 200025, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Taiyuan, 030001, China
-
Research Site
Wuhan, 430079, China
-
Research Site
Xi'an, 710061, China
-
Research Site
Brno, 656 53, Czechia
-
Research Site
Prague, 15006, Czechia
-
Research Site
Budapest, 1062, Hungary
-
Research Site
Budapest, 1082, Hungary
-
Research Site
Budapest, 1122, Hungary
-
Research Site
Milan, 20132, Italy
-
Research Site
Milan, 20141, Italy
-
Research Site
Modena, 41125, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Padova, 35128, Italy
-
Research Site
Roma, 00168, Italy
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Kōtoku, 135-8550, Japan
-
Research Site
Bydgoszcz, 85-796, Poland
-
Research Site
Gdansk, 80-214, Poland
-
Research Site
Gdynia, 81-519, Poland
-
Research Site
Grzepnica, 72-003, Poland
-
Research Site
Lodz, 90-302, Poland
-
Research Site
Torun, 87-100, Poland
-
Research Site
Warsaw, 02-781, Poland
-
Research Site
Moscow, 111123, Russia
-
Research Site
Moscow, 115478, Russia
-
Research Site
Moscow, 117997, Russia
-
Research Site
Moscow, 143442, Russia
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Madrid, 28040, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Madrid, 28050, Spain
-
Research Site
Málaga, 29010, Spain
-
Research Site
Pozuelo de Alarcón, 28223, Spain
-
Research Site
Seville, 41013, Spain
-
Research Site
Chernivtsі, 58013, Ukraine
-
Research Site
Ivano-Frankivsk, 76018, Ukraine
-
Research Site
Kyiv, 03022, Ukraine
-
Research Site
Uzhhorod, 88000, Ukraine
-
Research Site
Cambridge, CB2 0QQ, United Kingdom
-
Research Site
Manchester, M20 4BX, United Kingdom
-
Research Site
Oxford, OX3 7LE, United Kingdom
-
Research Site
Sutton, SM2 5PT, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD5305 (a PARP inhibitor drug taken by mouth)
What this could lead to
If it works, this could point toward a new treatment option for several advanced cancers, especially those with DNA repair problems.
What could go wrong
This is an early-phase trial, so the drug may not shrink tumors or may cause side effects. It is also tested in combination with chemotherapy, which can increase toxicity.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.